AHF Supports Development of Implant to Deliver HIV Drugs

In News by AHF

LOS ANGELES–(BUSINESS WIRE)–Today AIDS Healthcare Foundation President Michael Weinstein issued the following statement on findings recently published in the Antimicrobial Agents and Chemotherapy report that scientists from the Oak Crest Institute of Science have created the first subdermal implant that delivers antiretroviral drugs for up to 40 days to prevent or treat HIV:

“Numerous medical studies and our years of treating people living with HIV all over the world have proven to us that one of the most significant challenges in suppressing the virus is getting patients to take their medications every single day. From the beginning of the debate on pre-exposure prophylaxis as a public health strategy, AHF has said that we would support a vaccine or implant that reduces the human tendency to skip doses. While patient studies, federal approval, and information on pricing and availability is still needed at this early stage, the news that scientists have created the first implant to deliver HIV medications for prevention or treatment is a potential medical breakthrough that AHF wholeheartedly welcomes. We’ll be closely monitoring the next steps following these promising preliminary studies.”

 

Contacts

AHF
Ged Kenslea, Senior Director, Communications
+1.323.308.1833 work +1.323.791.5526 mobile
[email protected]th.org
or
AHF
Christopher Johnson, Associate Director of Communications
+1.323.960.4846 work +1.310.880.9913 mobile
[email protected]

Condoms in Porn Initiative Clears Important Threshold for 2016 California Statewide Ballot
Chicago: South Side Help Center & AHF Celebrate New Affiliation